Media Summary: For the very first time, the National Institute of Health held a Dr. Tiffany Farchione (Director – Psychiatry, Food & Drug Administration) in conversation with Brie Jackson (Deputy DC Bureau ... Psychiatry is at an inflection point. And the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, ...

Nih Conference On Psychedelic Treatment - Detailed Analysis & Overview

For the very first time, the National Institute of Health held a Dr. Tiffany Farchione (Director – Psychiatry, Food & Drug Administration) in conversation with Brie Jackson (Deputy DC Bureau ... Psychiatry is at an inflection point. And the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, ... The Food and Drug Administration says it is offering an “ultra-fast review” of two Brie Jackson (Deputy DC Bureau Chief, NewsNation) discusses next steps for Katrin Preller received her M.Sc. (Neuropsychology and Clinical Psychology) from University of Konstanz, Germany. She joined ...

Fred Barrett, Ph.D., Associate Director of the Johns Hopkins Center for Leaders of the Massachusetts General Hospital (MGH) Center for the Neuroscience of Adapted from lecture at Claremont McKenna College Thu, September 16, 2021 Alum, Daniel Kelly, M.D. '82, a neurosurgeon and ...

Photo Gallery

NIH conference on psychedelic treatment
Psychedelic Drug Development & Regulation | Rethinking Psychedelic Treatment for Mental Health
Rethinking Psychedelic Treatment for America's Mental Health Crisis
Dr. Collins, Director of NIH, testifies on Psychedelic Medicine
Psychedelics and the future of medicine
The future of psychedelic-assisted psychotherapy | Rick Doblin
Panel: Next Steps for Research & Care | Rethinking Psychedelic Treatment for Mental Health
Neurobiological Mechanisms of Psychedelics for Psychedelic-assisted Therapy | Dr. Katrin Preller
The Cognitive Neuroscience of Psychedelic Drugs - UC Davis Psychedelic Summit 2023
Psychedelics and Mental Health: Harnessing the Potential for Change to End Suffering
Psychedelic-Assisted Therapy: A New Dawn for Mental Health | Daniel Kelly, MD
Psychedelics Panel | Mental Healthcare Innovations Summit at Stanford Medicine
Sponsored
View Detailed Profile
NIH conference on psychedelic treatment

NIH conference on psychedelic treatment

For the very first time, the National Institute of Health held a

Psychedelic Drug Development & Regulation | Rethinking Psychedelic Treatment for Mental Health

Psychedelic Drug Development & Regulation | Rethinking Psychedelic Treatment for Mental Health

Dr. Tiffany Farchione (Director – Psychiatry, Food & Drug Administration) in conversation with Brie Jackson (Deputy DC Bureau ...

Rethinking Psychedelic Treatment for America's Mental Health Crisis

Rethinking Psychedelic Treatment for America's Mental Health Crisis

Psychiatry is at an inflection point. And the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, ...

Dr. Collins, Director of NIH, testifies on Psychedelic Medicine

Dr. Collins, Director of NIH, testifies on Psychedelic Medicine

Committee hearing full video: ...

Psychedelics and the future of medicine

Psychedelics and the future of medicine

The Food and Drug Administration says it is offering an “ultra-fast review” of two

Sponsored
The future of psychedelic-assisted psychotherapy | Rick Doblin

The future of psychedelic-assisted psychotherapy | Rick Doblin

Could

Panel: Next Steps for Research & Care | Rethinking Psychedelic Treatment for Mental Health

Panel: Next Steps for Research & Care | Rethinking Psychedelic Treatment for Mental Health

Brie Jackson (Deputy DC Bureau Chief, NewsNation) discusses next steps for

Neurobiological Mechanisms of Psychedelics for Psychedelic-assisted Therapy | Dr. Katrin Preller

Neurobiological Mechanisms of Psychedelics for Psychedelic-assisted Therapy | Dr. Katrin Preller

Katrin Preller received her M.Sc. (Neuropsychology and Clinical Psychology) from University of Konstanz, Germany. She joined ...

The Cognitive Neuroscience of Psychedelic Drugs - UC Davis Psychedelic Summit 2023

The Cognitive Neuroscience of Psychedelic Drugs - UC Davis Psychedelic Summit 2023

Fred Barrett, Ph.D., Associate Director of the Johns Hopkins Center for

Psychedelics and Mental Health: Harnessing the Potential for Change to End Suffering

Psychedelics and Mental Health: Harnessing the Potential for Change to End Suffering

Leaders of the Massachusetts General Hospital (MGH) Center for the Neuroscience of

Psychedelic-Assisted Therapy: A New Dawn for Mental Health | Daniel Kelly, MD

Psychedelic-Assisted Therapy: A New Dawn for Mental Health | Daniel Kelly, MD

Adapted from lecture at Claremont McKenna College Thu, September 16, 2021 Alum, Daniel Kelly, M.D. '82, a neurosurgeon and ...

Psychedelics Panel | Mental Healthcare Innovations Summit at Stanford Medicine

Psychedelics Panel | Mental Healthcare Innovations Summit at Stanford Medicine

The

Center for Psychedelic Psychotherapy & Trauma Research at Icahn School of Medicine at Mount Sinai

Center for Psychedelic Psychotherapy & Trauma Research at Icahn School of Medicine at Mount Sinai

The